Drug Resistance
miRNAs are known to play important roles in the diagnosis and prognosis of many cancers, and they are useful in developing targeted therapies.
Identification of novel molecular miRNAs and their target oncogenomic signatures have the potential to significantly impact clinical management.
Drug resistance (chemoresistance) is one of the major obstacles for improving the prognosis of cancer patients.
Increasing evidence has linked the association of aberrantly expressed microRNAs with acquired resistance of many cancer types and miRNA mimics and inhibitors may have potential clinical effects in the reversal of drug resistance.
Chemoresistance is one of the key causal factors in cancer death and emerging evidences suggest that miRNAs have critical roles in the regulation of chemo-sensitivity in cancers.
Acquired cancer chemoresistance is a multifactorial phenomenon, involving various mechanisms and processes. Despite recent advances, there is still little known about the potential role and mechanism of miRNAs in cancer chemoresistance.
Read more about how LC Sciences is helping clinicians and researchers to identify miRNA signatures associated with:
Read more about how LC Sciences is helping clinicians and researchers to identify mechanisms of resistance involving miRNAs and to better understand drug response associated with:
